Literature DB >> 3059788

Effects of antihypertensives on plasma lipids and lipoprotein metabolism.

W Krone1, H Nägele.   

Abstract

There is good epidemiologic evidence that hypertension is associated with a high risk of cardiovascular disease. However, primary intervention trials have failed to demonstrate that a reduction in blood pressure in hypertensive patients reduces morbidity and mortality from cardiac events. Since various antihypertensive drugs adversely affect lipoprotein metabolism, these drugs may increase associated coronary risk and offset the beneficial effects of lowering blood pressure. This article reviews the effects of various antihypertensive drugs on plasma lipids, lipoproteins, and apolipoproteins. They can be summarized as follows: thiazide-type diuretics cause a marked elevation of plasma triglycerides and very low-density lipoprotein (VLDL) and minor increases in total cholesterol and low-density lipoprotein (LDL), but have little effects on high-density lipoprotein (HDL). The nonselective beta-blockers do not significantly affect total cholesterol and LDL, but increase total triglycerides and VLDL and decrease HDL. The changes in plasma lipids and lipoproteins caused by cardioselective beta-blockers and beta-blockers with intrinsic sympathomimetic activity are qualitatively similar but less pronounced. Calcium antagonists and angiotensin-converting enzyme inhibitors appear to have no significant effects on plasma lipids. alpha 1-Inhibitors reduce total triglycerides, total cholesterol, VLDL, and LDL and increase HDL. The possible mechanisms by which antihypertensive drugs affect cellular lipid metabolism (e.g., LDL receptor, lipid synthesis, lipoprotein lipase, lecithin cholesteryl acyltransferase, acylcholesteryl acyltransferase, and cholesteryl ester hydrolase) are described. The clinical significance of changes in blood lipids and cellular lipid metabolism caused by antihypertensive drugs is not yet totally clear. Nevertheless, before antihypertensive drug treatment is initiated, blood lipid levels should be measured to identify preexisting hyperlipidemia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3059788     DOI: 10.1016/0002-8703(88)90222-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

1.  Effects of ivabradine on allograft function and exercise performance in heart transplant recipients with permanent sinus tachycardia.

Authors:  R Zhang; A Haverich; M Strüber; A Simon; M Pichlmaier; Christoph Bara
Journal:  Clin Res Cardiol       Date:  2008-07-21       Impact factor: 5.460

2.  A randomized controlled trial of the effects of aerobic dance training on blood lipids among individuals with hypertension on a thiazide.

Authors:  Fatai A Maruf; Aderonke O Akinpelu; Babatunde L Salako
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-06-24

3.  Effects of beta-blockers on HMG CoA reductase and LDL receptor activity in cultured human skin fibroblasts.

Authors:  H Yoshida; M Suzukawa; T Ishikawa; H Shige; E Nishio; H Hosoai; M Ayaori; H Nakamura
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

4.  Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance.

Authors:  Giuseppe Derosa; Arrigo F G Cicero; Angela D'Angelo; Pietro D Ragonesi; Leonardina Ciccarelli; Elena Fogari; Sibilla A T Salvadeo; Ilaria Ferrari; Alessia Gravina; Raffaella Fassi; Roberto Fogari
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

5.  Effects of treatment with verapamil SR and captopril on the lipid profile of hypertensive patients.

Authors:  M Catalano; C Cislaghi; G Carzaniga; A Aronica; R Seregni; A Libretti
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 6.  Goals of antihypertensive therapy.

Authors:  G E McVeigh; J Flack; R Grimm
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

Review 7.  Triglyceride Treatment in the Age of Cholesterol Reduction.

Authors:  Nidhi Agrawal; Patricia Freitas Corradi; Namrata Gumaste; Ira J Goldberg
Journal:  Prog Cardiovasc Dis       Date:  2016-08-17       Impact factor: 8.194

Review 8.  Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.

Authors:  S Sulfi; A D Timmis
Journal:  Int J Clin Pract       Date:  2006-02       Impact factor: 2.503

9.  Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry.

Authors:  Wen Yea Hwong; Zariah Abdul Aziz; Norsima Nazifah Sidek; Michiel L Bots; Sharmini Selvarajah; L Jaap Kappelle; Sheamini Sivasampu; Ilonca Vaartjes
Journal:  BMC Neurol       Date:  2017-11-23       Impact factor: 2.474

10.  Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome.

Authors:  Dion H Zappe; James R Sowers; Willa A Hsueh; Steven M Haffner; Prakash C Deedwania; Vivian A Fonseca; Lucy Keeling; Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-12       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.